Bristol-Myers Squibb Company Peer Comparison
| Metric | Value | Ranking | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $113.4 Billion | 8/9 | LLY $708.9B |
JNJ $349.0B |
ABBV $302.8B |
MRK $253.2B |
PFE $148.6B |
AMGN $144.6B |
GILD $115.1B |
BMY $113.4B |
BIIB $20.5B |
| Gross Margin | 75% | 3/9 | LLY 81% |
MRK 80% |
BMY 75% |
BIIB 74% |
ABBV 71% |
PFE 70% |
JNJ 70% |
AMGN 61% |
GILD -100% |
| Profit Margin | 10% | 8/9 | AMGN 33% |
PFE 25% |
MRK 19% |
GILD 17% |
BIIB 16% |
JNJ 12% |
ABBV 11% |
BMY 10% |
LLY 8% |
| EBITDA margin | 38% | 2/9 | ABBV 49% |
BMY 38% |
JNJ 32% |
PFE 31% |
MRK 25% |
AMGN 24% |
LLY 20% |
BIIB 18% |
GILD 12% |
| Quarterly Revenue | $11.9 Billion | 5/9 | JNJ $22.5B |
PFE $17.7B |
MRK $16.7B |
ABBV $14.5B |
BMY $11.9B |
LLY $11.4B |
AMGN $8.5B |
GILD $7.6B |
BIIB $2.5B |
| Quarterly Earnings | $1.2 Billion | 7/9 | PFE $4.5B |
MRK $3.2B |
AMGN $2.8B |
JNJ $2.7B |
ABBV $1.6B |
GILD $1.3B |
BMY $1.2B |
LLY $970.3M |
BIIB $388.5M |
| Quarterly Free Cash Flow | $5.3 Billion | 3/9 | MRK $8.5B |
PFE $6.1B |
BMY $5.3B |
ABBV $5.2B |
GILD $4.5B |
AMGN $3.3B |
BIIB $1.2B |
JNJ -$0 |
LLY -$458.9M |
| Trailing 4 Quarters Revenue | $47.4 Billion | 5/9 | JNJ $87.7B |
MRK $63.2B |
PFE $60.1B |
ABBV $55.5B |
BMY $47.4B |
LLY $40.9B |
AMGN $32.5B |
GILD $28.3B |
BIIB $9.5B |
| Trailing 4 Quarters Earnings | -$7.3 Billion | 9/9 | JNJ $22.5B |
PFE $17.7B |
MRK $16.7B |
ABBV $14.5B |
BMY $11.9B |
LLY $11.4B |
AMGN $8.5B |
GILD $7.6B |
BIIB $2.5B |
| Quarterly Earnings Growth | -37% | 7/9 | LLY 1790% |
BIIB 670% |
PFE 287% |
AMGN 64% |
ABBV -12% |
MRK -33% |
BMY -37% |
GILD -43% |
JNJ -90% |
| Annual Earnings Growth | -189% | 9/9 | MRK 192% |
LLY 60% |
BIIB -5% |
PFE -8% |
AMGN -28% |
ABBV -35% |
JNJ -65% |
GILD -98% |
BMY -189% |
| Quarterly Revenue Growth | 8% | 4/9 | PFE 34% |
AMGN 23% |
LLY 20% |
BMY 8% |
GILD 7% |
JNJ 5% |
ABBV 4% |
MRK 4% |
BIIB -3% |
| Annual Revenue Growth | 6% | 4/9 | LLY 330% |
PFE 17% |
AMGN 17% |
BMY 6% |
GILD 5% |
MRK 3% |
ABBV 0% |
BIIB -4% |
JNJ -10% |
| Cash On Hand | $7.9 Billion | 3/9 | MRK $14.6B |
AMGN $9.0B |
BMY $7.9B |
ABBV $7.3B |
LLY $3.4B |
BIIB $1.7B |
PFE $1.1B |
GILD -$0 |
JNJ -$0 |
| Short Term Debt | $1.1 Billion | 7/9 | ABBV $12.6B |
AMGN $3.5B |
MRK $3.1B |
PFE $2.9B |
LLY $2.1B |
BIIB $1.7B |
BMY $1.1B |
GILD -$0 |
JNJ -$0 |
| Long Term Debt | $48.7 Billion | 4/9 | ABBV $58.5B |
PFE $58.0B |
AMGN $56.9B |
BMY $48.7B |
MRK $35.0B |
LLY $29.0B |
BIIB $4.9B |
GILD $0 |
JNJ $0 |
| PE | -1.00 | 9/9 | GILD 913.73 |
LLY 84.70 |
ABBV 59.05 |
PFE 35.09 |
AMGN 34.18 |
JNJ 23.77 |
MRK 20.84 |
BIIB 12.72 |
BMY -1.00 |
| PS | 2.39 | 8/9 | LLY 17.35 |
ABBV 5.45 |
AMGN 4.45 |
GILD 4.07 |
MRK 4.01 |
JNJ 3.98 |
PFE 2.47 |
BMY 2.39 |
BIIB 2.16 |
| PB | 6.59 | 4/9 | ABBV 49.88 |
LLY 49.50 |
AMGN 19.21 |
BMY 6.59 |
MRK 5.68 |
JNJ 4.88 |
GILD 2.69 |
PFE 1.86 |
BIIB 1.20 |
| PC | 14.37 | 6/9 | LLY 210.42 |
PFE 136.07 |
ABBV 41.73 |
MRK 17.35 |
AMGN 16.04 |
BMY 14.37 |
BIIB 12.09 |
GILD -1.00 |
JNJ -1.00 |
| Liabilities to Equity | 4.46 | 3/9 | ABBV 22.77 |
AMGN 11.07 |
BMY 4.46 |
LLY 4.30 |
MRK 1.64 |
PFE 1.38 |
BIIB 0.66 |
GILD 0.00 |
JNJ -1.00 |
| ROA | -0.08 | 8/9 | LLY 11% | MRK 10% | BIIB 6% | AMGN 5% | ABBV 4% | PFE 2% | GILD 0% | BMY -8% | JNJ -100% |
| ROE | -0.42 | 8/9 | ABBV 85% |
LLY 59% |
AMGN 56% |
MRK 27% |
JNJ 21% |
BIIB 9% |
PFE 5% |
BMY -42% |
GILD -100% |
| Current Ratio | 1.22 | 6/9 | GILD 4.65 |
BIIB 2.53 |
PFE 1.63 |
MRK 1.61 |
LLY 1.23 |
BMY 1.22 |
AMGN 1.09 |
ABBV 1.04 |
JNJ 0.00 |
| Quick Ratio | 0.11 | 4/9 | GILD 913.73 |
LLY 84.70 |
ABBV 59.05 |
PFE 35.09 |
AMGN 34.18 |
JNJ 23.77 |
MRK 20.84 |
BIIB 12.72 |
BMY -1.00 |
| Long Term Debt to Equity | 2.84 | 3/9 | ABBV} 9.70 |
AMGN} 7.55 |
BMY} 2.84 |
LLY} 2.04 |
MRK} 0.79 |
PFE} 0.63 |
BIIB} 0.29 |
JNJ} 0.00 |
GILD} -1.00 |
| Debt to Equity | 2.90 | 3/9 | ABBV 11.78 |
AMGN 8.02 |
BMY 2.90 |
LLY 2.19 |
MRK 0.86 |
PFE 0.63 |
BIIB 0.29 |
JNJ 0.00 |
GILD -1.00 |
| Burn Rate | 7.85 | 2/9 | AMGN 27.29 |
BMY 7.85 |
BIIB 6.95 |
LLY 4.74 |
ABBV 1.85 |
GILD 0.00 |
JNJ 0.00 |
PFE -0.77 |
MRK -15.04 |
| Cash to Cap | 0.07 | 2/9 | BIIB 0.08 |
BMY 0.07 |
MRK 0.06 |
AMGN 0.06 |
ABBV 0.02 |
PFE 0.01 |
GILD 0.00 |
JNJ 0.00 |
LLY 0.00 |
| CCR | 4.35 | 1/9 | BMY 4.35 |
GILD 3.63 |
ABBV 3.33 |
BIIB 3.12 |
MRK 2.69 |
PFE 1.36 |
AMGN 1.17 |
JNJ 0.00 |
LLY -0.47 |
| EV to EBITDA | 33.91 | 9/9 | LLY} 327.70 |
GILD} 129.65 |
AMGN} 95.73 |
MRK} 67.66 |
BIIB} 52.66 |
ABBV} 52.05 |
JNJ} 49.16 |
PFE} 37.36 |
BMY} 33.91 |
| EV to Revenue | 3.27 | 8/9 | LLY 18.03 |
ABBV 6.60 |
AMGN 6.03 |
MRK 4.38 |
GILD 4.07 |
JNJ 3.98 |
PFE 3.42 |
BMY 3.27 |
BIIB 2.50 |